• Mara B. Antonoff, MD, FACS / Karen L. Reckamp, MD - Targeting Higher Standards in Resectable NSCLC: The Surgery-Oncology Coalition for Tailoring Care in EGFR and ALK TKI Therapy

  • Feb 14 2025
  • Durée: 53 min
  • Podcast

Mara B. Antonoff, MD, FACS / Karen L. Reckamp, MD - Targeting Higher Standards in Resectable NSCLC: The Surgery-Oncology Coalition for Tailoring Care in EGFR and ALK TKI Therapy

Écouter gratuitement

Voir les détails du balado

  • Résumé

  • This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.

    For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/CC/AAPA information, and to apply for credit, please visit us at PeerView.com/RDK865. CME/MOC/CC/AAPA credit will be available until February 25, 2026.

    Targeting Higher Standards in Resectable NSCLC: The Surgery-Oncology Coalition for Tailoring Care in EGFR & ALK TKI Therapy

    In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

    Support
    This activity is supported through independent educational grants from AstraZeneca and Genentech, a member of the Roche Group.

    Disclosure information is available at the beginning of the video presentation.

    Voir plus Voir moins
Voir plus Voir moins

Ce que les auditeurs disent de Mara B. Antonoff, MD, FACS / Karen L. Reckamp, MD - Targeting Higher Standards in Resectable NSCLC: The Surgery-Oncology Coalition for Tailoring Care in EGFR and ALK TKI Therapy

Moyenne des évaluations de clients

Évaluations – Cliquez sur les onglets pour changer la source des évaluations.

Évaluations sur Audible.ca

Évaluations sur Amazon.ca
Il n'y a pas encore de critiques pour ce titre.